| Symbol | MAP2K7 |
|---|
| Full Name | Mitogen-Activated Protein Kinase Kinase 7 |
|---|
| Alias | MEK7, MKK7, JNK kinase 2 |
|---|
| Chromosome | 19p13.3 |
|---|
| NCBI Gene ID | 5609 |
|---|
| UniProt ID | P45985 |
|---|
| Ensembl ID | ENSG00000100030 |
|---|
| Protein Family | MAP kinase kinase (MEK) family |
|---|
MAP2K7 (also known as MEK7 or MKK7) encodes mitogen-activated protein kinase kinase 7, a dual-specificity protein kinase that serves as the primary and most specific activator of the c-Jun N-terminal kinase (JNK) family. The MAP2K7-JNK signaling axis is a central mediator of cellular stress responses and plays critical roles in neuronal survival, synaptic plasticity, neuroinflammation, and neurodegeneration.
MEK7 is distinguished from other MAP2K family members by its unique specificity for JNK activation. Unlike MEK1/2 (which activate ERK1/2) or MEK3/6 (which activate p38 kinases), MEK7 exclusively activates the JNK isoforms (JNK1, JNK2, and JNK3). This specificity makes MAP2K7 a critical regulator of stress-activated signaling in the nervous system.
The MEK7 protein contains 447 amino acids and possesses a typical kinase domain structure. Alternative splicing generates multiple MEK7 isoforms with distinct expression patterns and regulatory properties. The isoforms differ in their N-terminal regions, which affect their subcellular localization and interaction partners.
The MAP2K7-JNK cascade is a central stress-activated signaling pathway:
flowchart TD
A["Stress Signals<br/>Cytokines<br/>Excitotoxicity"] --> B["MKK4/7"]
B --> C["JNK1/2/3"]
C --> D["c-Jun<br/>ATF2<br/>Elk-1"]
C --> E["Mitochondrial<br/>Pathways"]
C --> F["Synaptic<br/>Function"]
D --> G["Gene<br/>Transcription"]
E --> H["Apoptosis"]
F --> I["Synaptic<br/>Plasticity"]
G --> J["Inflammation<br/>Cell Death"]
MAP2K7 is activated by multiple stress signals:
- Cellular stress: Oxidative stress, DNA damage, ER stress
- Inflammatory cytokines: TNF-α, IL-1β, Fas ligand
- Excitotoxicity: Glutamate receptor overactivation
- Neurotoxic proteins: Aβ, α-synuclein, mutant huntingtin
- Growth factor withdrawal: Trophic factor deprivation
Three JNK genes encode multiple isoforms:
- JNK1 (MAPK8): Ubiquitously expressed, JNK1a and JNK1b splice variants
- JNK2 (MAPK9): Ubiquitously expressed, multiple isoforms
- JNK3 (MAPK10): Neuron-specific, primarily in brain and heart
MEK7 activates all three JNK isoforms, though with different efficiencies.
MAP2K7-JNK signaling regulates multiple aspects of brain development:
Neuronal Proliferation and Differentiation:
- Controls cell cycle exit in neural progenitors
- Regulates neuronal differentiation programs
- Essential for cortical layering
- Axon guidance and tract formation
Axon Growth and Guidance:
- JNK-mediated phosphorylation of MAP1B and SCG10
- Growth cone turning responses
- Axon regeneration capacity
- Cytoskeletal dynamics
The MEK7-JNK pathway modulates synaptic function:
Activity-Dependent Regulation:
- Response to synaptic activity
- AMPA receptor trafficking
- Spine morphogenesis
- LTP and LTD modulation
Transcription-Dependent Effects:
- c-Jun activation in neurons
- Immediate early gene expression
- Synaptic plasticity-related gene transcription
JNK signaling is central to neuronal stress responses:
Cellular Stress:
- Oxidative stress response
- DNA damage signaling
- ER stress response (UPR)
- Mitochondrial stress
Adaptive vs. Maladaptive JNK:
- Acute JNK activation: Adaptive, protective
- Chronic JNK activation: Maladaptive, contributes to disease
- Spatial specificity: Distinct pools have different functions
The MEK7-JNK pathway is heavily implicated in AD pathogenesis:
Amyloid-Beta Toxicity:
- Aβ activates JNK pathway in neurons
- JNK mediates Aβ-induced synaptic dysfunction
- JNK3 contributes to neuronal vulnerability
- Role in memory deficits
Tau Pathology:
- JNK phosphorylates tau at multiple sites
- Activation in NFT-bearing neurons
- Correlation with disease progression
- Interaction with GSK-3β
Synaptic Dysfunction:
- JNK-mediated spine loss
- Synaptic protein phosphorylation
- Impaired LTP
- Memory consolidation defects
Neuroinflammation:
- JNK in activated microglia
- Cytokine production
- Glial activation
JNK signaling is a key pathway in PD pathophysiology:
Dopaminergic Neuron Death:
- JNK activation in substantia nigra
- Response to mitochondrial toxins
- Role in apoptosis
- α-Synuclein toxicity mediation
Neuroinflammation:
- Microglial JNK activation
- Pro-inflammatory cytokine production
- Chronic neuroinflammation
Therapeutic Target:
- JNK inhibitors in development
- Neuroprotection in models
Motor Neuron Degeneration:
- JNK activation in ALS models
- SOD1-mediated toxicity
- Axonal degeneration[@morlish2022]
¶ Stroke and Brain Injury
The JNK pathway is activated in cerebral ischemia:
- Ischemia-reperfusion injury
- Excitotoxicity mediation
- Infarct expansion
- Therapeutic targeting potential
JNK signaling promotes neuronal death:
- Mitochondrial pathway activation
- BIM and other pro-apoptotic proteins
- Caspase activation
- Cytochrome c release
JNK in glial cells drives inflammation:
Microglial Activation:
- Cytokine production (TNF-α, IL-1β, IL-6)
- Migration and phagocytosis
- NADPH oxidase activation
- Chronic activation state
Astrocytic Response:
JNK impairs synaptic communication:
- AMPA receptor internalization
- Presynaptic terminal dysfunction
- Spine loss
- Impaired neurotransmitter release
JNK mediates axonal injury:[@morlish2022]
- SARM1-independent pathway
- Microtubule disruption
- Energy failure
- Progressive degeneration
Multiple JNK-targeted strategies are in development:
Small Molecule Inhibitors:
- SP600125: Pan-JNK inhibitor
- JNK-IN-8: Potent JNK inhibitor
- CC-930: JNK inhibitor in clinical trials
Therapeutic Approaches:
- Neuroprotection
- Anti-inflammatory effects
- Anti-apoptotic effects
- Blood-brain barrier penetration
- Isoform specificity
- Timing of intervention
- Side effects from pathway inhibition
MAP2K7 is expressed throughout the brain:
- High expression: Cerebral cortex, hippocampus, basal ganglia
- Cellular distribution: Neurons, astrocytes, microglia
- Isoform patterns: Different isoforms in different cell types
- Activity regulation: Activation by various stimuli
- Expressed during brain development
- Important for developmental processes
- Altered expression in disease states
MAP2K7 genetic variants have been associated with:
- Neurodevelopmental disorders: Some developmental conditions
- Psychiatric disorders: Depression, schizophrenia
- Cancer: Some somatic mutations
- Autoimmune conditions: Immune system disorders
- Pharmacogenomics of JNK inhibitors
- Biomarker potential
- Treatment response prediction
- Isoform-specific functions: What are the distinct roles of JNK1/2/3?
- Cell-type specificity: How does JNK function differ across cell types?
- Spatiotemporal dynamics: What are the precise activation patterns?
- Therapeutic targeting: How to achieve neuroprotection without side effects?
- Optogenetics: Light-controlled JNK activation
- Single-cell analysis: Cell-type specific functions
- Biomarkers: JNK activity as disease biomarker
- Combination therapy: JNK inhibition with other targets
¶ Protein Structure and Function
The MEK7 protein contains several key structural features:
Kinase Domain:
- Dual-specificity protein kinase domain
- Activation loop with phosphorylation sites (S272, T276)
- DFG motif for ATP binding
- Substrate docking domain
Isoforms:
- MEK7α1/α2: Different N-terminal variants
- MEK7β: Alternative splice form
- Isoform-specific localization and function
MEK7 phosphorylates JNK through:
- Activation: Phosphorylation of S272 and T276 by upstream MAPKKK
- JNK binding: D-domain mediated recruitment
- Catalysis: Phosphorylation of JNK T183 and Y185
- Termination: Phosphatase-mediated deactivation
MEK7 interacts with:
- MAPKKK: MEKK1-4, MLK, TAK1
- JNK: Primary substrate
- Scaffold proteins: JIP proteins for pathway assembly
- Phosphatases: MKP1, MKP7 for pathway termination
MAP2K7 and JNK knockout mice:
MEK7 Knockout:
- Embryonic lethal in most lines
- Tissue-specific knockouts reveal specific functions
- Neuron-specific deletion: Altered stress responses
JNK Knockouts:
- JNK1-/-, JNK2-/-: Viable, altered stress responses
- JNK3-/-: Protected from neuronal death
- Double knockouts: Enhanced phenotypes
JNK Transgenic:
- Neuronal JNK1 overexpression: Enhanced neurodegeneration
- JNK3 conditional: Disease model applications
Inhibitor Studies:
- D-JNKI1: Cell-permeable JNK inhibitor
- Peptide inhibitors: Target-based delivery
Learning and Memory:
- JNK inhibition: Enhanced memory
- JNK3 knockouts: Altered plasticity
Motor Function:
- Basal ganglia JNK in movement
- Dopaminergic neuron sensitivity
Emotional Behavior:
- JNK in stress responses
- Depression-related behaviors
ERK Pathway:
- Opposing functions in survival vs death
- Shared transcription factor targets
- Coordinated cellular responses
p38 Pathway:
- Common stress-activated upstream
- Complementary functions
- Parallel cellular outcomes
cAMP/PKA:
- Modulation of JNK activity
- Cross-talk at transcription factors
Calcium Signaling:
- Activity-dependent JNK activation
- Calmodulin interactions
NF-κB Pathway:
- Parallel inflammatory signaling
- Coordinated responses
Nuclear JNK:
- Transcriptional regulation
- c-Jun phosphorylation
- Gene expression programs
Cytoplasmic JNK:
- Cytoskeletal effects
- Mitochondrial effects
- Local signaling
Synaptic JNK:
- Synaptic plasticity modulation
- Spine-specific functions
JNK activity as clinical biomarker:
Diagnostic Applications:
- Disease state identification
- Subtype classification
- Early detection
Prognostic Applications:
- Outcome prediction
- Progression monitoring
- Treatment response
Therapeutic Monitoring:
- Target engagement
- Pathway modulation
- Efficacy measures
Direct JNK Inhibitors:
- SP600125, JNK-IN-8
- CC-930 in clinical trials
- Brain-penetrant compounds
Indirect Strategies:
- Upstream kinase inhibitors
- Transcription factor targets
- Downstream effectors
Combination Approaches:
- With neuroprotective agents
- With anti-inflammatory drugs
- With disease-modifying therapies
- Phase I/II trials for neurological disorders
- BBB-penetrant JNK inhibitors
- Biomarker-driven patient selection
- Combination trial designs
Substrate Specificity:
- High specificity for JNK isoforms
- Different Km for JNK1/2/3
- Vmax varies by isoform
Regulation:
- Dual phosphorylation on T183/Y185
- D-domain mediated interactions
- Phosphatase-mediated termination
Phosphorylation:
- T183 and Y185: Activation loop
- Additional regulatory sites
- Autophosphorylation
Other Modifications:
- Ubiquitination: Degradation
- Acetylation: Activity modulation
- Sumoylation: Localization
MEK7 in signaling complexes:
With JNK:
- JIP scaffold complexes
- MAPK module assemblies
- Nuclear-cytoplasmic shuttling
With Other Proteins:
- Upstream MAPKKK
- Phosphatases
- Substrate proteins
JNK in disease onset:
Early Events:
- Stress signal activation
- Synaptic dysfunction onset
- Initial cell stress responses
Progression Factors:
- Chronic JNK activation
- Inflammatory amplification
- Apoptosis execution
Factors affecting sensitivity:
- High JNK3 expression in neurons
- Limited JNK phosphatase activity
- Excitability-driven stress
¶ Models and Systems
Cell culture for JNK studies:
Primary Cells:
- Cortical neurons: Death mechanisms
- Hippocampal neurons: Synaptic effects
- Dopaminergic neurons: PD models
Cell Lines:
- HT-22: Oxidative stress
- SH-SY5Y: Differentiation
- NSC-34: ALS models
Animal models:
Knockout Mice:
- JNK1-/-: Viable
- JNK2-/-: Viable
- JNK3-/-: Protected neurons
Transgenic:
- JNK1/2 overexpression
- Dominant-negative JNK
- Reporter mice
Kinase Assays:
- In vitro phosphorylation
- Immunoprecipitation
- Activity-based probes
Phospho-antibodies:
- Phospho-JNK T183/Y185
- Phospho-c-Jun S63
- Pathway-specific detection
mRNA:
- qRT-PCR
- RNAseq
- In situ hybridization
Protein:
Rationale for JNK targeting:
- Central role in neuronal death
- Accessible activation loop
- Isoform-specific potential
Chemistry:
- Selectivity over other MAPKs
- Brain penetration
- Compound stability
Biology:
- Acute vs chronic timing
- Isoform-specific effects
- Compensation mechanisms
Potential uses:
- Acute neuroprotection
- Chronic disease modification
- Combination therapy